• SpectraCure posted a Q2 net loss of SEK 6.83 million, narrowing from SEK 7.2 million a year earlier.
• Other operating income fell 40.34% to SEK 210,000 in Q2.
• Operating cash flow turned negative to SEK 4.82 million outflow in Q2, from SEK 4.17 million inflow a year earlier.
• First-half net loss narrowed to SEK 12.97 million, while other operating income dropped 31.72% to SEK 521,000.
• Management said about 10 patients remain to complete Phase 2 in its prostate-cancer recurrence study, targeting completion by spring; a rights issue raised about SEK 25.7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpectraCure AB (publ) published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.